Clinical trials update from Heart Rhythm 2007 and Heart Failure 2007: CARISMA, PREPARE, DAVID II, SAVE-PACE, PROTECT and AREA-IN-CHF

European Journal of Heart Failure

Volumn 9, Issue 8, 2007, Pages 850-853

  Cleland, John G F ^a   Coletta, Alison P ^a   Abdellah, Ahmed Tageldien ^a   Witte, Klaus K ^b   Hobson, Neil ^a   Clark, Andrew L ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

^b LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

Heart failure; Randomised controlled trials

Indexed keywords

8 (2 NOR 1 ADAMANTYL) 1,3 DIPROPYLXANTHINE; ADENOSINE A1 RECEPTOR ANTAGONIST; ALDOSTERONE ANTAGONIST; CANRENONE; PLACEBO;

ABSENCE OF SIDE EFFECTS; ACUTE DISEASE; ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CARDIOVERSION; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFIBRILLATION; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM PACING; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE VOLUME; HEART VENTRICLE PACING; HUMAN; IMPLANTATION; KIDNEY DISEASE; MORTALITY; PATIENT SELECTION; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RISK ASSESSMENT; SCREENING TEST; SIDE EFFECT; SINUS NODE DISEASE; SUDDEN DEATH; TREATMENT INDICATION; TREATMENT OUTCOME;

ALDOSTERONE ANTAGONISTS; ARRHYTHMIAS, CARDIAC; CANRENONE; CARDIAC PACING, ARTIFICIAL; DEFIBRILLATORS, IMPLANTABLE; DIURETICS; HEART FAILURE; HUMANS; RISK ASSESSMENT; XANTHINES;

EID: 34547688960     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2007.07.003     Document Type: Article

References (14)

1. Kadish A., Dyer A., Daubert J.P., et al. defibrillators in non-ischemic cardiomyopathy treatment evaluation (DEFINITE) investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 350 (2004) 2151-2158
2. Moss A.J., Zareba W., Hall W.J., et al. for the multicenter automatic defibrillator implantation trial II investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346 (2002) 877-883
3. Bardy G.H., Lee K.L., Mark D.B., et al. sudden cardiac death in heart failure trial (SCD-HeFT) investigators. Amiodarone or an implantable cardioverter defibrillator for congestive heart failure. N Engl J Med 352 (2005) 225-237
4. Groeneveld P.W., Matta M.A., Suh J.J., Heidenreich P.A., and Shea J.A. Cost and quality of life effects of implantable cardioverter defibrillators. Am J Cardiol 98 (2006) 1409-1415
5. The DAVID trial investigators. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator. JAMA 288 (2002) 3115-3123
6. Thackray S.D.R., Ghosh J.M., Wright G.A., et al. The effects of altering heart rate on ventricular function in patients with heart failure treated with beta-blockers. Am Heart J 152 (2006) 713.e9-713.e13
7. Smith G.L., Lichtman J.H., Bracken M.B., et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol 47 (2006) 1987-1996
8. de Silva R., Nikitin N.P., Witte K.K., et al. Incidence of renal dysfunction over 6 months in patients with chronic heart failure due to left ventricular systolic dysfunction: contributing factors and relationship to prognosis. Eur Heart J 27 (2006) 569-581
9. Coletta A.P., Tin L., Loh H., Clark A.L., and Cleland J.G.F. Clinical trials update from the European Society of Cardiology heart failure meeting: TNT subgroup analysis, darbepoetin alfa, FERRIC-HF and KW-3902. Eur J Heart Fail 8 (2006) 547-549
10. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomised Aldactone Evaluation Study Investigators. N Engl J Med 341 (1999) 709-717
11. Pitt B., Remme W., Zannad F., et al. For the Eplerenone post-acute myocardial infarction heart failure efficacy and survival study investigators. Eplerenone, a selective aldosterone blocker in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 14 (2003) 1309-1321
12. Sanderson J., Chan A., Wang T., et al. The addition of spironolactone to an angiotensin receptor blocker induces reverse left ventricular remodelling in chronic heart failure. Heart 92 Suppl II (2006) 226 Abstract
13. Cleland J.G.F., Coletta A.P., and Clark A.L. Clinical trials update from the American College of Cardiology 2007: ALPHA, EVEREST, FUSION II, VALIDD, PARR-2, REMODEL, SPICE, COURAGE, COACH, REMADHE, pro-BNP for the evaluation of dyspnoea and THIS-diet. Eur J Heart Fail 9 (2007) 740-745
14. Shah N., Donnan P., Pringle S., and Struthers A. Evidence for a strong antiarrhythmic effect of spironolactone in patients with coronary heart disease but without heart failure. Heart 93 Suppl I (2007) 114 Abstract